AU613154B2 - Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants - Google Patents

Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants Download PDF

Info

Publication number
AU613154B2
AU613154B2 AU30243/89A AU3024389A AU613154B2 AU 613154 B2 AU613154 B2 AU 613154B2 AU 30243/89 A AU30243/89 A AU 30243/89A AU 3024389 A AU3024389 A AU 3024389A AU 613154 B2 AU613154 B2 AU 613154B2
Authority
AU
Australia
Prior art keywords
factor xiii
intraventricular hemorrhage
prevention
premature infants
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU30243/89A
Other languages
English (en)
Other versions
AU3024389A (en
Inventor
Akira Shirahata
Satoshi Tanaka
Kenichiro Tsumura
Minoru Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Publication of AU3024389A publication Critical patent/AU3024389A/en
Application granted granted Critical
Publication of AU613154B2 publication Critical patent/AU613154B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU30243/89A 1988-02-24 1989-02-23 Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants Expired AU613154B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-39646 1988-02-24
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (2)

Publication Number Publication Date
AU3024389A AU3024389A (en) 1989-08-24
AU613154B2 true AU613154B2 (en) 1991-07-25

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30243/89A Expired AU613154B2 (en) 1988-02-24 1989-02-23 Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants

Country Status (12)

Country Link
US (1) US5114916A (enExample)
EP (1) EP0330049B1 (enExample)
JP (1) JPH01216939A (enExample)
KR (1) KR0137476B1 (enExample)
AT (1) ATE94070T1 (enExample)
AU (1) AU613154B2 (enExample)
CA (1) CA1332352C (enExample)
DE (1) DE68908913T2 (enExample)
DK (1) DK174978B1 (enExample)
ES (1) ES2059588T3 (enExample)
IE (1) IE63656B1 (enExample)
PT (1) PT89802B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
JP3550685B2 (ja) * 1992-04-21 2004-08-04 味の素株式会社 創傷治療剤
ES2139729T3 (es) * 1992-11-12 2000-02-16 Zymogenetics Inc Uso del factor xiii aplicado topicamente para la inhibicion de hemorragias.
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
DE69925917T2 (de) 1998-08-06 2006-05-11 Mountain View Pharmaceuticals, Inc., Menlo Park PEG-Urikase Konjugate und Verwendung davon
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
AU2005308830B2 (en) * 2004-11-23 2012-01-19 Zymogenetics, Inc. Purification of recombinant human factor XIII
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
CN101622270B (zh) * 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7869487A (en) * 1986-09-19 1988-03-31 University Of Washington Expression of biologically active factor XIII

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7869487A (en) * 1986-09-19 1988-03-31 University Of Washington Expression of biologically active factor XIII

Also Published As

Publication number Publication date
KR0137476B1 (ko) 1998-06-01
DE68908913T2 (de) 1994-01-27
ATE94070T1 (de) 1993-09-15
EP0330049A3 (en) 1991-01-30
JPH0378850B2 (enExample) 1991-12-17
EP0330049A2 (en) 1989-08-30
AU3024389A (en) 1989-08-24
IE63656B1 (en) 1995-05-31
KR890012659A (ko) 1989-09-18
DE68908913D1 (de) 1993-10-14
PT89802A (pt) 1989-10-04
ES2059588T3 (es) 1994-11-16
CA1332352C (en) 1994-10-11
DK83889A (da) 1989-08-25
IE890580L (en) 1989-08-24
US5114916A (en) 1992-05-19
DK174978B1 (da) 2004-04-05
JPH01216939A (ja) 1989-08-30
PT89802B (pt) 1994-04-29
EP0330049B1 (en) 1993-09-08
DK83889D0 (da) 1989-02-23

Similar Documents

Publication Publication Date Title
AU613154B2 (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
Esmon The regulation of natural anticoagulant pathways
Long et al. Antiserum against tumor necrosis factor enhances lipopolysaccharide fever in rats
JPH02501028A (ja) トロンビンから誘導されたポリペプチド、組成物およびその使用方法
DK167738B1 (da) Fremgangsmaade til fremstilling af en oploesning med hoej specifik rumfangsaktivitet af et protein med vaevs-plasminogenaktivator(t-pa)-aktivitet, oploesning der indeholder protein med t-pa-aktivitet, og anvendelsen af oploesningen inden for human- og veterinaermedicinen
AU722743B2 (en) Stabilized aqueous liquid preparations of blood coagulation factor XIII
EP0278416B1 (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
Leimgruber et al. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy
CA2091134C (en) Therapeutic agent for threatened abortion
JPH05132427A (ja) プロテインｃ又は活性化プロテインｃの新規用途
US5164373A (en) Therapeutic agent for diabetic gangrene comprising factor XIII
EP0691850B1 (en) Factor xiii for treatment of skin wounds
Tarter et al. A clinical study of the use of intravenous urea in glaucoma
RU2119316C1 (ru) Способ лечения кровоизлияний во внутренние среды и оболочки глаза
JP2698782B2 (ja) 脳動脈瘤破裂防止剤
Nadal Inhibition of hepatocyte proliferation in vivo by a glycopeptide from rat serum
JOHNSON et al. of a Factor VIII Concentrateđ
JPH0495031A (ja) 血栓溶解活性増強剤
Shapiro Clinical disorders of the factor VIII molecule
JPH09176041A (ja) α２プラスミンインヒビターを含有するＤＩＣ治療用薬剤